These possibilities are worth pursuing, given the evidence that GRM3 contributes to the genetic risk for schizophrenia, and in light of the continuing focus on group II metabotropic glutamate receptors as therapeutic targets. This evidence concerns the gene GRM3 and schizophrenia.